ArticleThe American journal of sports medicine2026
Impact of Significant Coracoid Graft Resorption on Clinical Outcomes After Arthroscopic Latarjet Procedure: Development and Validation of a Refined Classification System for Coracoid Bone Graft Resorption.
Article in The American journal of sports medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical impact of coracoid graft resorption after the Latarjet procedure has been controversial and likely underestimated. PURPOSE: To (1) develop and validate a refined classification system-coracoid graft resorption based on degree and location (CRDL); and (2) correlate clinical and radiological outcomes with the CRDL classification system. STUDY
designCohort study; Level of evidence, 3.
methodsBetween January 2015 and December 2018, 63 patients who underwent the arthroscopic Latarjet procedure were evaluated with computed tomography imaging preoperatively, immediately postoperatively, and at a minimum 5-year follow-up. According to the resorption location, the coracoid graft resorption was classified as grade 0 (no resorption), grade 1 (resorption on the proximal-medial and/or distal-medial part), grade 2 (resorption on the proximal-lateral part with no resorption on the distal-lateral part), and grade 3 (resorption on the distal-lateral part). Resorption severity was categorized as mild (grades 0 and 1) and severe (grades 2 and 3). The incidence, classification, and location of graft resorption were described. Intrarater and interrater reliability were calculated. Correlations between the classification and clinical and radiological outcomes were analyzed.
resultsAfter a mean follow-up of 85.3 months, coracoid graft resorption was observed in 84.1% of cases: grade 0 in 15.9%, grade 1 in 47.6%, grade 2 in 30.2%, and grade 3 in 6.3%. Mild and severe resorption were found in 63.5% and 36.5% of patients, respectively. Resorption mainly occurred on the proximal-medial part of the graft. Intra- and interrater reliability of the classification system were both almost perfect (κ = 0.865 and 0.822, respectively). Significant differences were found in the postoperative American Shoulder and Elbow Surgeons (ASES) and visual analog scale for pain (VAS) scores among different grades and between mild and severe resorption. Correlation and multivariable regression analyses identified higher-grade graft resorption as a risk factor for worse postoperative ASES and VAS scores.
conclusionCRDL classification is a reliable and clinically relevant classification system for coracoid graft resorption evaluation. Application of the CRDL system reveals that while high-grade resorption is a significant risk factor for postoperative shoulder pain, it has no major impact on shoulder function or stability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.